Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition.

Autor:	Cao Zhang, Alexander M., Ziogos, Efthymios, Harb, Tarek, Gerstenblith, Gary, Leucker, Thorsten M.
Předmět:	ACUTE coronary syndrome LIPID metabolism ATHEROSCLEROTIC plaque RANDOMIZED controlled trials SUBTILISINS
Zdroj:	European Journal of Clinical Investigation; Oct2024, Vol. 54 Issue 10, p1-14, 14p
Abstrakt:	Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as a novel class of drugs with cardioprotective effects through their lipid‐lowering effects. Objective: This review aims to discuss existing and novel strategies of PCSK9 inhibition, providing an overview of established randomized controlled trials and ongoing outcome trials that assess the efficacy and long‐term safety of PCSK9 inhibitors. It also explores the evolving role of PCSK9 beyond lipid metabolism and outlines the pleiotropic actions of PCSK9 inhibition in various disorders and future directions including novel strategies to target PCSK9. Conclusion: PCSK9 inhibition shows promise not only in lipid metabolism but also in other disease processes, including atherosclerotic plaque remodeling, acute coronary syndrome, stroke, inflammation, and immune response. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text